secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-06-05T23:59:59+00:00
Accession:  0001171843-24-003302
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Phase 2a: imdusiran+IFN yields sustained undetectable HBsAg in 33% at 24 weeks
--------------------------------------------------------------------------------

- 33.3% (4/12) on 48wk imdusiran + 24wk IFN had undetectable HBsAg at EOT, sustained 24wk post-treatment.
- All six patients with sustained HBsAg loss seroconverted with high anti-HBsAg antibodies (43.8 to >1,000 mIU/mL).
- Two of six patients stopped all therapy and maintain undetectable HBsAg and HBV DNA at 12 weeks off therapy.
- No SAEs related to imdusiran or IFN; most common TEAEs were transient ALT elevations and injection site bruising.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324003302/0001171843-24-003302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324003302/f8k_060424.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-003302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer